Roni Nielsen1, Anders Jorsal2,3, Peter Iversen4, Lars Poulsen Tolbod4, Kirsten Bouchelouche4, Jens Sørensen4, Hendrik Johannes Harms4, Allan Flyvbjerg5, Lise Tarnow6, Caroline Kistorp7, Ida Gustafsson8, Hans Erik Bøtker2, Henrik Wiggers2,3. 1. Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark. roni.r.nielsen@gmail.com. 2. Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark. 3. Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark. 4. Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, Denmark. 5. Faculty of Health, Aarhus University, Aarhus, Denmark. 6. Steno Diabetes Center, Gentofte, Denmark. 7. Department of Endocrinology and Internal Medicine, Herlev University Hospital, Copenhagen, Denmark. 8. Department of Cardiology, Hvidovre University Hospital, Copenhagen, Denmark.
Abstract
BACKGROUND: The glucagon-like peptide-1 analog liraglutide increases heart rate and may be associated with more cardiac events in chronic heart failure (CHF) patients. We studied whether this could be ascribed to effects on myocardial glucose uptake (MGU), myocardial blood flow (MBF) and MBF reserve (MFR). METHODS AND RESULTS:CHF patients with left ventricular ejection fraction ≤45% and without type 2 diabetes were randomized to liraglutide (N = 18) 1.8 mg once daily or placebo (N = 18) for 24 weeks in a double-blinded design. Changes in MGU during an oral glucose tolerance test (OGTT) and changes in MBF and MFR from baseline to follow-up were measured quantitatively by 18F-FDG and 15O-H2O positron emission tomography. Compared with placebo, liraglutide reduced weight (P = 0.03), HbA1c (P = 0.03) and the 2-hour glucose value during the OGTT (P = 0.004). Despite this, changes in MGU (P = 0.98), MBF (P = 0.76) and MFR (P = 0.89) from baseline to follow-up did not differ between groups. Furthermore, there was no association between the level of insulin resistance at baseline and changes in MGU in patients treated with liraglutide. CONCLUSION:Liraglutide did not affect MGU, MBF, or MFR in non-diabetic CHF patients. Any potential increase in cardiac events in these patients seems not to involve changes in MGU, MBF, or MFR. TRIAL REGISTRATION: Trial registry: http://www.ClinicalTrials.org . Identifier: NCT01472640. Url: https://clinicaltrials.gov/ct2/show/NCT01472640?term=NCT01472640&rank=1.
RCT Entities:
BACKGROUND: The glucagon-like peptide-1 analog liraglutide increases heart rate and may be associated with more cardiac events in chronic heart failure (CHF) patients. We studied whether this could be ascribed to effects on myocardial glucose uptake (MGU), myocardial blood flow (MBF) and MBF reserve (MFR). METHODS AND RESULTS:CHFpatients with left ventricular ejection fraction ≤45% and without type 2 diabetes were randomized to liraglutide (N = 18) 1.8 mg once daily or placebo (N = 18) for 24 weeks in a double-blinded design. Changes in MGU during an oral glucose tolerance test (OGTT) and changes in MBF and MFR from baseline to follow-up were measured quantitatively by 18F-FDG and 15O-H2O positron emission tomography. Compared with placebo, liraglutide reduced weight (P = 0.03), HbA1c (P = 0.03) and the 2-hour glucose value during the OGTT (P = 0.004). Despite this, changes in MGU (P = 0.98), MBF (P = 0.76) and MFR (P = 0.89) from baseline to follow-up did not differ between groups. Furthermore, there was no association between the level of insulin resistance at baseline and changes in MGU in patients treated with liraglutide. CONCLUSION: Liraglutide did not affect MGU, MBF, or MFR in non-diabetic CHFpatients. Any potential increase in cardiac events in these patients seems not to involve changes in MGU, MBF, or MFR. TRIAL REGISTRATION: Trial registry: http://www.ClinicalTrials.org . Identifier: NCT01472640. Url: https://clinicaltrials.gov/ct2/show/NCT01472640?term=NCT01472640&rank=1.
Entities:
Keywords:
Heart failure; clinical studies; echocardiography; metabolism; nuclear cardiology and PET
Authors: Betsy B Dokken; W Ronald Hilwig; Mary K Teachey; R Ashish Panchal; Karl Hubner; Daniel Allen; David C Rogers; Karl B Kern Journal: Resuscitation Date: 2010-03-26 Impact factor: 5.262
Authors: Christoph Rischpler; Nicolas Langwieser; Michael Souvatzoglou; Anja Batrice; Sandra van Marwick; Julian Snajberk; Tareq Ibrahim; Karl-Ludwig Laugwitz; Stephan G Nekolla; Markus Schwaiger Journal: Eur Heart J Cardiovasc Imaging Date: 2015-02-13 Impact factor: 6.875
Authors: Maulik D Majmudar; Venkatesh L Murthy; Ravi V Shah; Swathy Kolli; Negareh Mousavi; Courtney R Foster; Jon Hainer; Ron Blankstein; Sharmila Dorbala; Arkadiusz Sitek; Lynne W Stevenson; Mandeep R Mehra; Marcelo F Di Carli Journal: Eur Heart J Cardiovasc Imaging Date: 2015-02-25 Impact factor: 6.875
Authors: Arpita Kalla Vyas; Kai-Chien Yang; Dennis Woo; Anatoly Tzekov; Attila Kovacs; Patrick Y Jay; Paul W Hruz Journal: PLoS One Date: 2011-02-17 Impact factor: 3.240
Authors: Karpagam Aravindhan; Weike Bao; Mark R Harpel; Robert N Willette; John J Lepore; Beat M Jucker Journal: PLoS One Date: 2015-06-22 Impact factor: 3.240
Authors: Rebekka Faber; Mette Zander; Adam Pena; Marie M Michelsen; Naja D Mygind; Eva Prescott Journal: Cardiovasc Diabetol Date: 2015-04-22 Impact factor: 9.951
Authors: Kieren J Mather; Robert V Considine; LaTonya Hamilton; Niral A Patel; Carla Mathias; Wendy Territo; Adam G Goodwill; Johnathan D Tune; Mark A Green; Gary D Hutchins Journal: J Clin Endocrinol Metab Date: 2018-09-01 Impact factor: 5.958
Authors: Yuliya Lytvyn; Petter Bjornstad; Jacob A Udell; Julie A Lovshin; David Z I Cherney Journal: Circulation Date: 2017-10-24 Impact factor: 29.690
Authors: Malin Nilsson; Kira Bang Bové; Elena Suhrs; Thomas Hermann; Sten Madsbad; Jens Juul Holst; Eva Prescott; Mette Zander Journal: Int J Cardiol Heart Vasc Date: 2019-01-29
Authors: Trevor Yeong; Aaron Shengting Mai; Oliver Z H Lim; Cheng Han Ng; Yip Han Chin; Phoebe Tay; Chaoxing Lin; Mark Muthiah; Chin Meng Khoo; Mayank Dalakoti; Poay-Huan Loh; Mark Chan; Tiong-Cheng Yeo; Roger Foo; Raymond Wong; Nicholas W S Chew; Weiqin Lin Journal: ESC Heart Fail Date: 2022-01-29